Targeted toxins in cancer immunotherapy

Devalingam Mahalingam, Michael J. Brumlik, Reinhard Waehler, David T. Curiel, Tyler J. Curiel

Research output: Chapter in Book/Report/Conference proceedingChapter


Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy: Paradigms, Practice and Promise
PublisherSpringer New York
Number of pages20
ISBN (Print)9781461447320, 1461447313, 9781461447313
StatePublished - May 1 2013

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Targeted toxins in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this